PMID- 34897888
OWN - NLM
STAT- MEDLINE
DCOM- 20220325
LR  - 20220325
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 31
IP  - 3
DP  - 2022 Mar
TI  - Initiation of quarterly palmitate paliperidone in French clinical practice: 
      Results from the observational, cross-sectional OPTIMUS study.
PG  - 334-342
LID - 10.1002/pds.5397 [doi]
AB  - PURPOSE: Long-term antipsychotic treatment is key to a positive clinical outcome 
      in schizophrenia. Recent guidelines recommend the prescription of long-acting 
      antipsychotic formulations (LAIs) as early as the first episode in patients with 
      schizophrenia. The OPTIMUS study evaluated real-world use of a new three-monthly 
      paliperidone palmitate formulation (PP3M) in France. METHODS: For this 
      observational cross-sectional study, all French psychiatrists were invited to 
      enrol patients who had initiated PP3M in the previous 4 months. Snapshot data 
      were collected at a routine consultation, without any modification of clinical 
      practice. RESULTS: This population of 350 patients with schizophrenia started on 
      PP3M predominantly included single men, living independently with a diagnosis of 
      schizophrenia for a median of 9.3 years. Demographic characteristics were broadly 
      comparable to those reported in other studies on LAIs. Investigators cited 
      treatment simplification (96.9%) and patient comfort (93.3%) as the most common 
      reasons for switching to PP3M; enhancing adherence was mentioned less often 
      (61.1%) with most patients previously considered as adherent, and a majority of 
      them expressing a positive attitude to their treatment. One-third of patients 
      accepted the psychiatrist's proposal to initiate PP3M treatment without any 
      discussion, and relatives were involved in the therapeutic decision-making 
      process in only 23.7% of cases. After initiation, few changes were seen in 
      professional follow-up frequency or concomitant pharmacological and 
      non-pharmacological treatment modalities except for a decrease in antipsychotic 
      polytherapy. CONCLUSIONS: PP3M is mostly prescribed in adherent patients with 
      fairly stable schizophrenia, and the longer dosing interval does not 
      substantially affect patient care.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Gary, Charlotte
AU  - Gary C
AD  - Medical Affairs Department, Janssen, Issy-les-Moulineaux, France.
FAU - Deal, Cecile
AU  - Deal C
AD  - Medical Affairs Department, Janssen, Issy-les-Moulineaux, France.
FAU - Boursicot-Beuzelin, Jennifer
AU  - Boursicot-Beuzelin J
AD  - Medical Affairs Department, Janssen, Issy-les-Moulineaux, France.
FAU - Falissard, Bruno
AU  - Falissard B
AD  - Paris-Descartes University, Maison de Solenn, Paris, France.
FAU - Giordana, Jean-Yves
AU  - Giordana JY
AD  - Association Hospitaliere Sainte-Marie, Centre Hospitalier Sainte-Marie, Nice, 
      France.
FAU - Fakra, Eric
AU  - Fakra E
AD  - Centre Hospitalier Universitaire de Saint-Etienne, Hopital de la Charite, 
      Saint-Etienne, France.
FAU - Samalin, Ludovic
AU  - Samalin L
AD  - Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, 
      CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, 
      France.
FAU - Bouju, Sophie
AU  - Bouju S
AD  - Medical Affairs Department, Janssen, Issy-les-Moulineaux, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220106
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Palmitates)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - *Antipsychotic Agents/therapeutic use
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Male
MH  - Paliperidone Palmitate/therapeutic use
MH  - Palmitates/therapeutic use
MH  - *Schizophrenia/drug therapy/epidemiology
OTO - NOTNLM
OT  - clinical study
OT  - paliperidone palmitate
OT  - patient profile
OT  - real-world
OT  - schizophrenia
EDAT- 2021/12/14 06:00
MHDA- 2022/03/26 06:00
CRDT- 2021/12/13 13:53
PHST- 2021/11/02 00:00 [revised]
PHST- 2021/07/05 00:00 [received]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2022/03/26 06:00 [medline]
PHST- 2021/12/13 13:53 [entrez]
AID - 10.1002/pds.5397 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2022 Mar;31(3):334-342. doi: 10.1002/pds.5397. Epub 
      2022 Jan 6.